Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Clinical trial NCT05306847 · UNKNOWN

Trial details

NCT number: NCT05306847
Sponsor: Peking Union Medical College Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2022-04-01
Primary completion: 2024-04-01
Enrollment: 93

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.